نتایج جستجو برای: chek2

تعداد نتایج: 669  

2015
Ondrej Havranek Petra Kleiblova Jan Hojny Filip Lhota Pavel Soucek Marek Trneny Zdenek Kleibl Alvaro Galli

The checkpoint kinase 2 gene (CHEK2) codes for the CHK2 protein, an important mediator of the DNA damage response pathway. The CHEK2 gene has been recognized as a multi-cancer susceptibility gene; however, its role in non-Hodgkin lymphoma (NHL) remains unclear. We performed mutation analysis of the entire CHEK2 coding sequence in 340 NHL patients using denaturing high-performance liquid chromat...

2016
Stian Knappskog Beryl Leirvaag Liv B. Gansmo Pål Romundstad Kristian Hveem Lars Vatten Per E. Lønning

BACKGROUND While germline CHEK2 mutations have been linked to a moderately elevated cancer risk, to date, a limited number of such mutations have been identified. Recently, we reported a germline nonsense mutation (C283T; R95*), introducing an early stop-codon, in two Norwegian patients diagnosed with locally advanced breast cancer. Both patients were resistant to anthracycline therapy, resembl...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006
Jonine L Bernstein Sharon N Teraoka Esther M John Irene L Andrulis Julia A Knight Robert Lapinski Eric R Olson Abigail L Wolitzer Daniela Seminara Alice S Whittemore Patrick Concannon

CHEK2, a serine-threonine kinase, is activated in response to agents, such as ionizing radiation, which induce DNA double-strand breaks. Activation of CHEK2 can result in cell cycle checkpoint arrest or apoptosis. One specific variant, CHEK2*1100delC, has been associated with an increased risk of breast cancer. In this population-based study, we screened 2,311 female breast cancer cases and 496...

Journal: :Cancer research 2008
Shiyu Zhang Catherine M Phelan Phil Zhang Francois Rousseau Parviz Ghadirian Andre Robidoux William Foulkes Nancy Hamel David McCready Maureen Trudeau Henry Lynch Douglas Horsman Maria Lourdes Leon De Matsuda Zeba Aziz Magda Gomes Mauricio Magalhaes Costa Alexander Liede Aletta Poll Ping Sun Steven A Narod

A founder allele in the CHEK2 gene (1100delC) has been associated with an elevated risk of breast cancer. This allele is responsible for the majority of CHEK2-associated breast cancers in women from northern European countries; however, within Europe, it seems to be rare in countries that are close to the Mediterranean. The frequency of the 1100delC allele has not been measured in non-White pop...

2004
Justo Lorenzo Bermejo Alfonso García Pérez Kari Hemminki

The known breast cancer susceptibility genes only account for 20% to 25% of the excess familial risk of the disease 1. The present study assessed the contribution of BRCA1/2 mutations and CHEK2 variants to the relative risk of breast cancer for women with affected mothers or sisters. The familial relative risks were estimated by Poisson regression based on the Swedish Family-Cancer Database. Th...

Journal: :Journal of medical genetics 2003
O Kilpivaara P Laiho L A Aaltonen H Nevanlinna

C ell cycle checkpoint kinase 2 (CHEK2) is a tumour suppressor involved in the p53 pathway of DNA damage responses. Upon ionizing radiation induced DNA damage, CHEK2 is activated by ataxia telangiectasia mutated (ATM) and is in turn capable of phosphorylating several substrates including Cdc25A, Cdc25C, p53, and BRCA1, leading to cell cycle arrest, apoptosis, and DNA repair (reviewed in Bartek ...

Journal: :Journal of medical genetics 2004
G H de Bock M Schutte E M M Krol-Warmerdam C Seynaeve J Blom C T M Brekelmans H Meijers-Heijboer C J van Asperen C J Cornelisse P Devilee R A E M Tollenaar J G M Klijn

BACKGROUND The germline CHEK2*1100delC variant has been associated with breast cancer in multiple case families where involvement of BRCA1 and BRCA2 has been excluded. METHODS We have investigated the tumour characteristics and prognosis of carriers of this germline variant by means of a prospective cohort study in an unselected cohort of 1084 consecutive patients with primary breast cancer. ...

2003
O Kilpivaara P Laiho L A Aaltonen H Nevanlinna

C ell cycle checkpoint kinase 2 (CHEK2) is a tumour suppressor involved in the p53 pathway of DNA damage responses. Upon ionizing radiation induced DNA damage, CHEK2 is activated by ataxia telangiectasia mutated (ATM) and is in turn capable of phosphorylating several substrates including Cdc25A, Cdc25C, p53, and BRCA1, leading to cell cycle arrest, apoptosis, and DNA repair (reviewed in Bartek ...

Journal: :Balkan journal of medical genetics : BJMG 2015
I Maleva Kostovska M Jakimovska K Kubelka-Sabit M Karadjozov A Arsovski L Stojanovska D Plaseska-Karanfilska

Clinical importance of the most common CHEK2 (IVS2+1 G>A, 1100delC, I157T and del5395) and NBN (R215W and 657del5) gene mutations for breast cancer development in Macedonian breast cancer patients is unknown. We performed a case-control study including 300 Macedonian breast cancer patients and 283 Macedonian healthy controls. Genotyping was done using a fast and highly accurate single-nucleotid...

2009
Ranjan Chrisanthar Stian Knappskog Erik Løkkevik Gun Anker Bjørn Østenstad Steinar Lundgren Elisabet O. Berge Terje Risberg Ingvil Mjaaland Lovise Mæhle Lars Fredrik Engebretsen Johan Richard Lillehaug Per Eystein Lønning

Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously found TP53 mutations in the L2/L3 domai...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید